VACCITECH (SP.ADR)/1 Net Assets
VACCITECH (SP.ADR)/1 net assets. Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) has net assets worth €66.48 Million EUR (≈ $77.72 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€92.14 Million ≈ $107.72 Million USD) and total liabilities (€25.66 Million ≈ $30.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore VACCITECH (SP.ADR)/1 (2AB) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €66.48 Million |
| % of Total Assets | 72.15% |
| Annual Growth Rate | -26.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.2 |
Net Assets of VACCITECH (SP.ADR)/1 (2021–2025)
Net assets of VACCITECH (SP.ADR)/1 from 2021 to 2025. This chart illustrates how VACCITECH (SP.ADR)/1's net assets have evolved over time, based on quarterly financial data. See 2AB net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for VACCITECH (SP.ADR)/1 (2021–2025)
The table below shows the annual net assets of VACCITECH (SP.ADR)/1 from 2021 to 2025. For live market cap and overall valuation, see market cap of VACCITECH (SP.ADR)/1.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €74.29 Million ≈ $86.86 Million |
-42.91% |
| 2024-12-31 | €130.13 Million ≈ $152.14 Million |
-30.41% |
| 2023-12-31 | €187.00 Million ≈ $218.62 Million |
-23.11% |
| 2022-12-31 | €243.20 Million ≈ $284.33 Million |
-3.71% |
| 2021-12-31 | €252.56 Million ≈ $295.27 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VACCITECH (SP.ADR)/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19550700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
VACCITECH (SP.ADR)/1 Net Assets Breakdown (December 2025)
VACCITECH (SP.ADR)/1 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €378.30 Million | 509.78% |
| Total Equity | €74.21 Million | 100.00% |
VACCITECH (SP.ADR)/1 Competitors by Market Cap
The table below lists competitors of VACCITECH (SP.ADR)/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
$20.63 Million |
|
Nova Agritech Ltd.
NSE:NOVAAGRI
|
$20.63 Million |
|
MegaMD Co. Ltd
KQ:133750
|
$20.63 Million |
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
$20.65 Million |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
$20.62 Million |
|
Bangsaphan Barmill Public Company Limited
BK:BSBM
|
$20.62 Million |
|
Lithium Energy Ltd
AU:LEL
|
$20.60 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
$20.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VACCITECH (SP.ADR)/1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 130,029,000 to 74,208,000, a change of -55,821,000 (-42.9%).
- Net loss of 66,428,000 reduced equity.
- Other factors increased equity by 10,607,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-66.43 Million | -89.52% |
| Other Changes | €10.61 Million | +14.29% |
| Total Change | €- | -42.93% |
Book Value vs Market Value Analysis
This analysis compares VACCITECH (SP.ADR)/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.78 | €0.51 | x |
| 2022-12-31 | €6.45 | €0.51 | x |
| 2023-12-31 | €4.83 | €0.51 | x |
| 2024-12-31 | €3.23 | €0.51 | x |
| 2025-12-31 | €1.82 | €0.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VACCITECH (SP.ADR)/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-89.52%) is below the historical average (-38.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -20.17% | -18979.48% | 0.00x | 1.11x | €-76.08 Million |
| 2022 | 2.20% | 11.95% | 0.17x | 1.11x | €-18.95 Million |
| 2023 | -39.27% | -9145.51% | 0.00x | 1.15x | €-92.03 Million |
| 2024 | -46.97% | -408.00% | 0.09x | 1.23x | €-74.08 Million |
| 2025 | -89.52% | 0.00% | 0.00x | 1.32x | €-73.85 Million |
Industry Comparison
This section compares VACCITECH (SP.ADR)/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VACCITECH (SP.ADR)/1 (2AB) | €66.48 Million | -20.17% | 0.39x | $20.62 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About VACCITECH (SP.ADR)/1
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more